Vaxnewmo

St. Louis, MO

UEI
HVUWF1K69W37
CAGE
7PBE6
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
4447 McPherson Ave, St. Louis, MO 63108, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A multivalent o-antigen bioconjugate vaccine for the prevention of klebsiella pneumoniae infections R42AI165116 National Institute of Allergy and Infectious Diseases (NIH) $5,878,981
A capsule-based bioconjugate vaccine to prevent klebsiella pneumoniae infections R44AI167078 National Institute of Allergy and Infectious Diseases (NIH) $1,999,022
A capsule-based bioconjugate vaccine to prevent klebsiella pneumoniae infections R41AI167078 National Institute of Allergy and Infectious Diseases (NIH) $1,186,224
Development of a group b streptococcus bioconjugate vaccine R44AI142928 National Institute of Allergy and Infectious Diseases (NIH) $3,991,364
Development of a bioconjugate vaccine against group b streptococcus R41AI142928 National Institute of Allergy and Infectious Diseases (NIH) $580,104

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
The Washington University The goal of this project is to have Dr. Harding and colleagues at Omniose produce and characterize various bioconjugate vaccines targeting O-antigens or… R01AI195492 $80,721
The Washington University Scope of Work for the Co-Investigator Dr. Christian Harding of Omniose on R01AI175038-01A1 entitled “Protective immunity elicited by distinct polysaccharide… R01AI175038 $92,593
The Washington University Scope of Work for the Co-Investigator Dr. Christian Harding of Omniose on R01AI175038-01A1 entitled “Protective immunity elicited by distinct… R01AI175038 $173,415
The Washington University Scope of Work for the Co-Investigator Dr. Christian Harding of Omniose on R01AI175038-01A1 entitled “Protective immunity elicited by distinct… R01AI175038 $167,915

Similar vendors

Vendor Location Primary NAICS
Vaxcyte, Inc. UEI Y56EGX9CCTE5 San Carlos, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Gangagen Biotechnologies Private LIMITED UEI FCHHM8JKZNE6 Bengaluru, KA —
Sciogen LLC UEI RGEHAJ63EJK5 Los Altos, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Centivax, Inc. UEI GDKVJMCM5KQ6 South San Francisco, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Basilea Pharmaceutica International Ltd, Allschwil UEI UA43HWRNXFS3 Allschwil, BL 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Vaxnewmo is a for-profit biotechnology company focused on developing conjugate vaccines to prevent bacterial infections. Through various prime and sub federal grant awards, Vaxnewmo develops conjugate vaccine candidates targeting Klebsiella pneumoniae, Group B Streptococcus, and other pathogens.

Vaxnewmo has received over $3.6 million in prime federal grant awards from the National Institutes of Health to advance development of bioconjugate vaccines for Klebsiella pneumoniae and Group B Streptococcus infections. This includes a recent $896K prime grant from National Institute of Allergy and Infectious Diseases to develop a multivalent O-antigen bioconjugate vaccine targeting K. pneumoniae, as well as a $1.2M prime grant to develop a capsule-based tetravalent bioconjugate vaccine against hypervirulent and carbapenem-resistant K. pneumoniae strains. Vaxnewmo also received a $1M prime grant from NIAID to further develop a trivalent bioconjugate vaccine against leading Group B Streptococcus serotypes that cause neonatal meningitis and sepsis. Additionally, Vaxnewmo has received a federal sub-award from Washington University to produce various O-antigen and K-antigen bioconjugate vaccines as tools to study immune evasion by Klebsiella pneumoniae.

Quick answers

Is Vaxnewmo registered in SAM.gov?

Yes. Vaxnewmo's SAM.gov registration is active through February 3, 2027.

What is Vaxnewmo's most recent federal award?

Vaxnewmo's most recent federal grant award is A multivalent o-antigen bioconjugate vaccine for the prevention of klebsiella pneumoniae infections (R42AI165116), from National Institute of Allergy and Infectious Diseases (NIH), on July 15, 2022.

On GovTribe

See Vaxnewmo's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login